Ropinirole

What it is

Ropinirole is a synthetic non-ergoline dopamine agonist taken as a tablet; the label recorded here is the immediate-release tablet. It is not derived from ergot alkaloids, which is what 'non-ergoline' means, and it acts directly on dopamine receptors rather than being converted into dopamine. In the United States it is approved for Parkinson's disease and for moderate-to-severe primary restless legs syndrome. It is extensively metabolised by the liver enzyme CYP1A2 and has an elimination half-life of about six hours.

What the research says

The evidence is strongest for two things and weaker than most people assume for a third. For early Parkinson's disease, a five-year randomised trial and a Cochrane meta-analysis agree that starting with a dopamine agonist rather than levodopa reduces dyskinesia, but at the price of worse symptom control and far more dropouts for side effects; the pragmatic PD MED trial found patient-rated mobility slightly better with levodopa. For restless legs syndrome, a Cochrane meta-analysis found a real but modest symptom reduction over trials lasting up to about seven months, with longer-term data thin and augmentation poorly measured. Added to levodopa for established motor complications, a Cochrane review found no significant 'off' time benefit and more dyskinesia. The harm literature is substantial: impulse control disorders, augmentation in restless legs, somnolence and sudden sleep onset, and a withdrawal syndrome on stopping.

Evidence grade: Well established.

How it works

Drug class: Non-ergoline dopamine D2/D3 receptor agonist

Ropinirole switches on dopamine receptors in the brain directly, standing in for the dopamine that is lost in Parkinson's disease. The label is clear that the exact way this helps is not known for either approved use; the working idea is stimulation of D2 receptors in the caudate-putamen, the movement-control region. (Source 1)

What it is used for

• Randomised evidence over five years shows ropinirole-first treatment lowers the cumulative incidence of dyskinesia from about 45% to about 20% compared with levodopa-first treatment, but Cochrane and the pragmatic PD MED trial both find symptom control is poorer and side-effect dropouts much higher than with levodopa. Evidence: established. (Source 2)
• A Cochrane review of three trials in 263 patients found no significant reduction in daily 'off' time, a significant increase in dyskinesia, and a useful reduction in levodopa dose; the review judged the trials small, short and poorly reported. Evidence: limited. (Source 3)
• Dopamine agonists as a class beat placebo on the IRLS severity scale by about 5.7 points in a Cochrane meta-analysis of 7,365 patients, with more adverse events and dropouts; a dedicated 66-week trial found augmentation, a worsening of the condition caused by the drug, in 3.5% on ropinirole versus under 1% on placebo. Evidence: established. (Source 4)
• A 20-patient phase 1/2a trial found no difference from placebo in the rate of ALSFRS-R functional decline over its 24-week blinded period; a benefit appeared only in the unblinded extension, which the authors themselves limit by small sample size and high attrition. Evidence: not-supported. (Source 5)

Interactions

• Ciprofloxacin and other CYP1A2 inhibitors (pharmacokinetic study): Ciprofloxacin blocks the enzyme that clears ropinirole, so blood levels rise substantially and side effects such as sleepiness and nausea become more likely. (Source 6)
• Oestrogens containing ethinylestradiol, including in oral contraceptives (pharmacokinetic study): Oestrogens slow the clearance of ropinirole by about a third, so starting or stopping HRT can change how much drug is in the body at the same dose. (Source 6)
• Hormone replacement therapy, started or stopped (label): Higher-dose oestrogens of the kind used in hormone replacement therapy slow the body's clearance of ropinirole, so the same tablet gives a higher blood level. The label says that starting or stopping HRT may mean the ropinirole dose has to be changed. (Source 7)
• Tobacco smoking (pharmacokinetic study): Smoking induces CYP1A2 and so speeds up clearance of ropinirole; in one restless legs trial smokers had about 30% lower peak levels and 38% lower total exposure than non-smokers at the same dose. Stopping smoking can therefore raise drug levels. (Source 8)
• A high-fat meal (pharmacokinetic study): Taking ropinirole with a high-fat meal does not change the total amount absorbed, but it delays the peak by about 2.5 hours and lowers the peak concentration by roughly 25%. (Source 9)
• Alcohol and other sedating substances (label): The label warns of additive sedation when ropinirole is combined with alcohol or other central nervous system depressants, on top of a baseline somnolence rate of 40% versus 6% on placebo in early Parkinson's trials. (Source 10)

Stopping it

• A withdrawal syndrome is documented on tapering or stopping dopamine agonists: insomnia, apathy, anxiety, depression, fatigue, sweating and pain, which generally do not respond to levodopa. The label advises informing patients beforehand and monitoring during and after discontinuation. (Source 11)
• A retrospective chart review of 126 Parkinson's patients in whom a dopamine agonist was stopped found dopamine agonist withdrawal syndrome in 16.8%, and reported that no standard treatment exists other than reintroducing the agonist. (Source 12)
• In restless legs syndrome the label recommends reducing the daily dose gradually rather than stopping abruptly, and reviewing treatment if augmentation or early-morning rebound appears. (Source 13)

What goes wrong

The same Cochrane review reported that symptom control was poorer with dopamine agonists than with levodopa and that agonist users were far more likely to stop treatment because of side effects. (Source 14)

• Meta-analysis, Moderate certainty.
• Size: 29 trials, 5,247 participants.
• Who: Adults with early Parkinson's disease.
• How long: Trial durations varied.
• Result: Discontinuation due to adverse events OR 2.49 (95% CI 2.08 to 2.98; P < 0.00001); symptom control better with levodopa but data too inconsistent to meta-analyse.
• Funding: Independent (Cochrane systematic review)

Agonist-treated participants were also significantly more likely to discontinue treatment due to adverse events (OR 2.49, 95% CI 2.08 to 2.98; P < 0.00001). Finally symptomatic control of Parkinson's disease was better with levodopa than with agonists, but data were reported too inconsistently and incompletely to meta-analyse.

A prospective 66-week trial designed specifically to count augmentation found it in 3.5% of ropinirole-treated patients versus under 1% on placebo during the blinded phase, with new cases still accruing at a steady rate at the end of the study. (Source 15)

• Randomized trial, Moderate certainty.
• Size: 404 patients in the 26-week double-blind phase, 269 in the 40-week open-label phase.
• Who: Adults with primary restless legs syndrome and no previous history of augmentation.
• How long: 66 weeks total.
• Result: Augmentation incidence 3.5% ropinirole vs <1% placebo in the double-blind phase and 3% during open-label; incidence 3.1% higher with ropinirole than placebo; 42% discontinuation rate overall; treatment stopped in 7 of 14 patients with augmentation.
• Funding: Not stated in the recorded abstract; the paper describes a postmarketing multicentre ropinirole programme.

Limit of this finding: The published abstract has a printing error in the sentence describing the design: 'followed by 40 weeks of open-label ropinirole treatment..' carries a double full stop. It is a stray character in the paper, reproduced here because quotations are kept exactly as printed; no text is missing from the sentence and nothing should be read into it.

The incidence rates of augmentation were 3.5% for ropinirole and <1% for placebo during the DB phase and 3% during the open-label phase. Clinically significant augmentation occurred in 3%, <1%, and 2%, respectively. Discontinuation of treatment occurred in 50% of all patients (7 of 14) with augmentation. The incidence of augmentation was 3.1% higher with ropinirole than with placebo. New patients with first episodes of augmentation continued to cumulate at a stable rate over the duration of this study.

A cross-sectional study of 3,090 treated Parkinson's patients found impulse control disorders in 17.1% of those on a dopamine agonist versus 6.9% of those not on one, with ropinirole and pramipexole carrying similar frequencies. (Source 16)

• Survey study, Moderate certainty.
• Size: 3,090 patients with treated idiopathic Parkinson disease at 46 movement disorder centres.
• Who: Patients receiving routine clinical care in the United States and Canada.
• How long: Point prevalence, cross-sectional.
• Result: ICD in 13.6% overall; 17.1% on a dopamine agonist vs 6.9% not (OR 2.72, 95% CI 2.08-3.54; P < .001); ropinirole 15.5% vs pramipexole 17.7% (OR 1.22, 95% CI 0.94-1.57; P = .14)
• Funding: Research Support, Non-U.S. Gov't per the record; the DOMINION study was supported by Boehringer Ingelheim.

Impulse control disorders were more common in patients treated with a dopamine agonist than in patients not taking a dopamine agonist (17.1% vs 6.9%; odds ratio [OR], 2.72; 95% confidence interval [CI], 2.08-3.54; P < .001). Impulse control disorder frequency was similar for pramipexole and ropinirole (17.7% vs 15.5%; OR, 1.22; 95% CI, 0.94-1.57; P = .14).

Because this is a cross-sectional design, the DOMINION investigators described an association between dopamine agonist treatment and impulse control disorders, not a demonstrated cause. (Source 17)

• Survey study, Low certainty.
• Size: 3,090 patients.
• Who: Patients with treated idiopathic Parkinson disease.
• How long: Cross-sectional.
• Result: 2- to 3.5-fold increased odds of an ICD, described as a drug class relationship.
• Funding: Research Support, Non-U.S. Gov't per the record.

Dopamine agonist treatment in PD is associated with 2- to 3.5-fold increased odds of having an ICD. This association represents a drug class relationship across ICDs.

A retrospective chart review found a dopamine agonist withdrawal syndrome in 21 of the 126 Parkinson's patients whose agonist was stopped, about one in six, with higher agonist doses, a previous impulse control disorder and previous deep brain stimulation all associated with it. (Source 12)

• Cohort study, Low certainty.
• Size: 313 charts reviewed; 126 patients had the dopamine agonist discontinued; 21 met DAWS criteria.
• Who: Parkinson's disease patients treated with a dopamine agonist at one centre, 2011-2013.
• How long: Retrospective over 3 years of records.
• Result: DAWS in 21 of 126 patients, printed in the paper as 16.8% (21/126 is 16.7%); associated with dose >=150 mg levodopa-equivalents (p=0.018), impulse control disorder (p=0.002) and prior deep brain stimulation (p=0.049); probability 92% with all three factors and 3% with none.
• Funding: Not stated in the recorded abstract.

Limit of this finding: The paper prints the rate as '16.8 %', but 21 out of 126 is 16.7%; the published figure only works against a denominator of 125. The arithmetic slip is in the paper and has been left as printed in the quotation. Take the rate as about one in six. Note too that a review of one centre's past records can show which features occurred alongside the syndrome but cannot establish that any of them brought it on.

Twenty-one patients (16.8 %) fulfilled the diagnostic criteria for DAWS. Factors associated with the occurrence of DAWS were: (1) dose of dopamine agonist ≥150 mg expressed in levodopa equivalents daily dose (LEDD) (p = 0.018), (2) impulse control disorder as an adverse effect to dopamine agonist (p = 0.002), and (3) prior deep brain stimulation (DBS)

The FDA label records intense urges to gamble, increased sexual urges, compulsive spending and binge eating as reported effects of ropinirole, sometimes stopping when the dose is reduced or the drug withdrawn. (Source 18)

• Official position, Certainty not rated.
• Size: Not stated (postmarketing reports)
• Who: People taking ropinirole for Parkinson's disease or RLS.
• How long: Not stated.
• Result: No rates given in this label section; the label asks prescribers to question patients and consider dose reduction or stopping.
• Funding: Not applicable (regulatory label, Alembic Pharmaceuticals, SPL version 22, published Sep 30 2026)

Reports suggest that patients can experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge or compulsive eating, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including ropinirole tablets, that increase central dopaminergic tone.

In placebo-controlled early Parkinson's disease trials recorded in the label, 24% of ropinirole patients stopped for adverse reactions versus 13% on placebo, with nausea, somnolence, dizziness and syncope the commonest problems. (Source 19)

• Randomized trial, Moderate certainty.
• Size: 157 ropinirole and 147 placebo patients in the tabulated early-PD trials.
• Who: Adults with early-stage Parkinson's disease not taking levodopa.
• How long: Premarketing double-blind placebo-controlled trials, duration not stated in this section.
• Result: Discontinuation for adverse reactions 24% ropinirole vs 13% placebo; commonest reactions at least 5% above placebo were nausea, somnolence, dizziness, syncope, asthenic condition, viral infection, leg oedema, vomiting and dyspepsia.
• Funding: Industry (data generated by the sponsor for FDA approval)

Approximately 24% of patients treated with ropinirole tablets who participated in the double-blind, placebo-controlled early Parkinson’s disease (without L-dopa) trials discontinued treatment due to adverse reactions compared with 13% of patients who received placebo.

In the placebo-controlled trials of ropinirole added to levodopa in advanced Parkinson's disease recorded on the label, about 24% of ropinirole patients stopped treatment for adverse reactions against 18% on placebo. (Source 20)

• Randomized trial, Moderate certainty.
• Size: Not stated in this label section; the trials are the double-blind placebo-controlled advanced Parkinson's disease programme.
• Who: Patients with advanced-stage Parkinson's disease already taking L-dopa.
• How long: Not stated in this label section.
• Result: Discontinuation for adverse reactions approximately 24% on ropinirole versus 18% on placebo, dizziness the commonest reason; dyskinesia, somnolence, nausea, dizziness, confusion, hallucinations, increased sweating and headache each at least 5% more frequent than placebo.
• Funding: Not stated (manufacturer's label)

Approximately 24% of patients who received ropinirole tablets in the double-blind, placebo-controlled advanced Parkinson’s disease (with L-dopa) trials discontinued treatment due to adverse reactions compared with 18% of patients who received placebo.

What the evidence supports

A five-year randomised double-blind trial in early Parkinson's disease found starting with ropinirole rather than levodopa cut the five-year cumulative incidence of dyskinesia from 45% to 20%, an absolute difference of about 25 percentage points. (Source 2)

• Randomized trial, Moderate certainty.
• Size: 268 patients randomised (179 ropinirole, 89 levodopa)
• Who: Adults with early Parkinson's disease, levodopa supplementation allowed open-label.
• How long: 5 years.
• Result: Cumulative incidence of dyskinesia at 5 years 20% (36 of 177) with ropinirole vs 45% (40 of 88) with levodopa; hazard ratio for remaining free of dyskinesia 2.82 (95% CI 1.78 to 4.44), P<0.001.
• Funding: Industry-funded (conducted by SmithKline Beecham as the ropinirole 056 study); funding statement not in the abstract text recorded.

At five years, the cumulative incidence of dyskinesia (excluding the three patients who had dyskinesia at base line), regardless of levodopa supplementation, was 20 percent (36 of 177 patients) in the ropinirole group and 45 percent (40 of 88 patients) in the levodopa group.

What the evidence does not support

In the same five-year trial there was no significant difference between ropinirole and levodopa in change in activities-of-daily-living scores, and withdrawal for adverse events was common in both arms. (Source 2)

• Randomized trial, Moderate certainty.
• Size: 268 patients randomised.
• Who: Adults with early Parkinson's disease.
• How long: 5 years.
• Result: No significant difference in mean change in activities of daily living scores among completers; early withdrawal for adverse events in 48 of 179 (27%) on ropinirole and 29 of 89 (33%) on levodopa.
• Funding: Industry-funded (ropinirole 056 study); funding statement not in the abstract text recorded.

There was no significant difference between the two groups in the mean change in scores for activities of daily living among those who completed the study.

PD MED, a large pragmatic open-label trial, found that starting Parkinson's treatment with a dopamine agonist or MAO-B inhibitor instead of levodopa gave slightly worse patient-rated mobility, and that 28% of the agonist group stopped treatment for side effects versus 2% of the levodopa group. (Source 21)

• Randomized trial, Moderate certainty.
• Size: 1,620 patients (528 levodopa, 632 dopamine agonist, 460 MAOBI)
• Who: Patients newly diagnosed with Parkinson's disease in UK, Czech and Russian clinics.
• How long: Median 3 years' follow-up, observation to 7 years.
• Result: PDQ-39 mobility 1.8 points better with levodopa (95% CI 0.5-3.0, p=0.005), against a stated minimally important difference of six points; 179 (28%) of 632 on dopamine agonists vs 11 (2%) of 528 on levodopa discontinued for side-effects (p<0.0001)
• Funding: Independent (UK National Institute for Health Research HTA Programme and UK Department of Health)

179 (28%) of 632 patients allocated dopamine agonists and 104 (23%) of 460 patients allocated MAOBI discontinued allocated treatment because of side-effects compared with 11 (2%) of 528 patients allocated levodopa (p<0·0001).

A Cochrane review of ropinirole added to levodopa for established motor complications found no significant reduction in 'off' time but a significant increase in dyskinesia. (Source 3)

• Systematic review, Low certainty.
• Size: 3 double-blind randomised trials, 263 patients.
• Who: Adults with Parkinson's disease already on levodopa with motor complications.
• How long: 12 to 26 weeks.
• Result: Difference in off-time reduction non-significant (weighted mean difference 0.19 hours, 95% CI -0.63 to 1.00); dyskinesia increased, OR 2.59 (95% CI 1.35 to 4.96; p < 0.004); levodopa dose reduction greater on ropinirole (WMD 136.5 mg/d, 95% CI 74.5 to 198.6)
• Funding: Independent Cochrane review; data supplied in part by the manufacturer (SmithKline Beecham contacted)

Additional data from the manufacturer showed that the difference in the reduction in off time was non-significantly greater with ropinirole than placebo (weighted mean difference [WMD] 0.19 hours; -0.63, 1.00 95% CI). As an adverse event, dyskinesia was significantly increased in those who received ropinirole (odds ratio [OR] 2.59; 1.35, 4.96 95% CI; p < 0.004).

A phase 1/2a trial of ropinirole in amyotrophic lateral sclerosis, an off-label use, did not show a difference from placebo in the rate of ALSFRS-R decline during its 24-week blinded period. (Source 5)

• Randomized trial, Very low certainty.
• Size: 20 participants with sporadic ALS.
• Who: Adults with sporadic amyotrophic lateral sclerosis, single centre in Japan.
• How long: 24 weeks double-blind plus 24-week open-label extension.
• Result: Decline in ALSFRS-R during the double-blind period not different from placebo; in the open-label extension the ropinirole group showed suppression of ALSFRS-R decline and an additional 27.9 weeks of disease-progression-free survival; authors note small sample size and high attrition.
• Funding: Not stated in the recorded abstract; the ROPALS programme was funded by the Japan Agency for Medical Research and Development and K Pharma Inc.

During the double-blind period, muscle strength and daily activity were maintained, but a decline in the ALSFRS-R, which assesses the functional status of ALS patients, was not different from that in the placebo group.

Where the evidence is mixed

A Cochrane meta-analysis of dopamine agonists versus levodopa as first treatment for Parkinson's disease found fewer motor complications but worse symptom control and more non-motor side effects with agonists. (Source 14)

• Meta-analysis, Moderate certainty.
• Size: 29 trials, 5,247 participants.
• Who: Adults with early Parkinson's disease.
• How long: Trial durations varied; up to 5 years.
• Result: Dyskinesia OR 0.51 (95% CI 0.43 to 0.59); oedema OR 3.68 (2.62 to 5.18); somnolence OR 1.49 (1.12 to 2.00); hallucinations OR 1.69 (1.13 to 2.52); discontinuation for adverse events OR 2.49 (2.08 to 2.98)
• Funding: Independent (Cochrane systematic review)

Participants randomised to a dopamine agonist were less likely to develop dyskinesia (odds ratio (OR) 0.51, 95% confidence interval (CI) 0.43 to 0.59; P < 0.00001), dystonia (OR 0.64, 95% CI 0.51 to 0.81; P = 0.0002) and motor fluctuations (OR 0.75, 95% CI 0.63 to 0.90; P = 0.002) than levodopa-treated participants.

A Cochrane meta-analysis of dopamine agonists for restless legs syndrome found a mean 5.7-point greater reduction in the IRLS severity score than placebo, but also more adverse events and more dropouts, and it stated that augmentation was not reliably measured. (Source 4)

• Meta-analysis, Moderate certainty.
• Size: 38 randomised trials, N = 7,365.
• Who: Adults with restless legs syndrome.
• How long: At least 7 days; only four studies went to about seven months.
• Result: IRLS -5.7 points vs placebo (95% CI -6.7 to -4.7); PLMS index -22.4/h (95% CI -27.8 to -16.9); dropout OR 1.82 (1.35 to 2.45); adverse events OR 1.82 (1.59 to 2.08)
• Funding: Independent (Cochrane review); authors contacted pharmaceutical companies for data.

Limit of this finding: The review prints the same odds ratio, 1.82, for two different outcomes - dropping out of a trial (95% CI 1.35 to 2.45) and having an adverse event (95% CI 1.59 to 2.08). The two intervals differ, so these are two separate analyses, but an identical point estimate for both may be a transcription slip in the published abstract. Read each as 'roughly twice the odds of placebo' rather than as an exact figure. This review also covers dopamine agonists as a class - cabergoline, pergolide, pramipexole and levodopa among them - so none of its numbers is specific to ropinirole.

The mean reduction on the IRLS was -5.7 points lower in dopamine agonist treatment compared to placebo (95% confidence interval (CI) -6.7 to -4.7). Periodic limb movements in sleep per hour of sleep (PLMS-Index; PLMSI) were -22.4/h lower than in placebo (95% CI -27.8 to -16.9). Self rated quality of sleep and disease specific quality of life were improved by a standardised mean difference (SMD) of 0.40 (95% CI 0.33 to 0.47) and 0.34 (95% CI 0.23 to 0.44), respectively. Patients were more likely to drop out (odds ratio (OR) 1.82, 95% CI 1.35 to 2.45) and experienced more adverse events under dopamine agonist treatment than with placebo (OR 1.82, 95% CI 1.59 to 2.08). Visual inspection of forest plots showed the highest efficacy in three studies investigating cabergoline and pergolide (N = 3). Active controlled trials investigated effects of cabergoline, pergolide, and pramipexole in a number of outcomes. The IRLS score was lower with cabergoline and pramipexole compared to levodopa (MD -5.3, 95% CI -8.4 to -2.1). Only four studies investigated treatment efficacy up to seven months. The most severe side effect, augmentation, was not assessed reliably.

Where the research disagrees

Whether Parkinson's disease should be started on a dopamine agonist such as ropinirole or on levodopa

• Rascol and colleagues, five-year randomised double-blind trial (2000), randomised controlled trial with dyskinesia as the primary outcome: At five years, the cumulative incidence of dyskinesia (excluding the three patients who had dyskinesia at base line), regardless of levodopa supplementation, was 20 percent (36 of 177 patients) in the ropinirole group and 45 percent (40 of 88 patients) in the levodopa group. (Source 2)
• PD MED collaborative group, large pragmatic open-label randomised trial (2014), pragmatic randomised trial with patient-rated quality of life as the primary outcome: Very small but persistent benefits are shown for patient-rated mobility scores when treatment is initiated with levodopa compared with levodopa-sparing therapy. MAOBI as initial levodopa-sparing therapy was at least as effective as dopamine agonists. (Source 22)
• Cochrane review of dopamine agonist therapy in early Parkinson's disease (2008), meta-analysis of randomised trials comparing dopamine agonists with levodopa as initial therapy: This meta-analysis confirms that motor complications are reduced with dopamine agonists compared to levodopa, but also establishes that other important side-effects are increased and symptom control is poorer with agonists. (Source 23)

How much

• Reference intake: Dosing is set by the prescriber, not by the reader. As a position, the FDA label (Alembic ropinirole tablets, SPL version 22, published Sep 30 2026) states a restless legs starting dose of 0.25 mg once daily 1 to 3 hours before bedtime, titrated by individual response and tolerability up to a maximum recommended dose of 4 mg daily, above which safety and effectiveness have not been established for that use. (Source 24)
• Upper limit: As a position, the same label gives a maximum recommended total daily dose of 24 mg/day (8 mg 3 times daily) for Parkinson's disease and states that doses greater than 24 mg/day have not been tested in clinical trials. The restless legs ceiling of 4 mg daily is set in a separate section of the same label. (Source 25)
• Studied: In the five-year early Parkinson's disease trial the mean daily dose reached by the end of the study was 16.5 +/- 6.6 mg of ropinirole, with 427 +/- 221 mg of levodopa in those who needed supplementation. (Source 2)
• Studied: The 66-week restless legs augmentation study used 26 weeks of double-blind flexible-dose ropinirole or placebo followed by 40 weeks of open-label ropinirole. (Source 15)

A common belief, and what the research shows

The belief: Because ropinirole lowers the risk of dyskinesia, it is simply the safer way to start Parkinson's treatment.

What the research shows: The trade is real but two-sided. The Cochrane meta-analysis of 29 trials and 5,247 participants found dyskinesia, dystonia and motor fluctuations all reduced with agonists, and then stated that other important side-effects are increased and symptom control is poorer: This meta-analysis confirms that motor complications are reduced with dopamine agonists compared to levodopa, but also establishes that other important side-effects are increased and symptom control is poorer with agonists.

Questions and answers

What is it?

Ropinirole is a prescription tablet, not a nutrient or a substance the body makes. It is a non-ergoline dopamine agonist, meaning it is a synthetic molecule that switches on the brain's dopamine receptors directly rather than replacing dopamine. The FDA label covers two uses: Parkinson's disease and moderate-to-severe primary restless legs syndrome. (Source 26)

What does it do in the body?

It stimulates dopamine D2 receptors in the part of the brain that controls movement. The label is explicit that the precise mechanism for both Parkinson's disease and restless legs syndrome is not known, only inferred from that receptor action. (Source 1)

Is it good or bad for you?

It depends entirely on the setting. In early Parkinson's disease a five-year randomised trial found it roughly halved the risk of developing dyskinesia compared with levodopa, but a large pragmatic trial found patient-rated mobility slightly worse and side-effect dropout fourteen times higher than levodopa. In restless legs syndrome it reduces symptom scores by about six points on the IRLS scale short term, but it can cause augmentation, which makes the condition worse than before treatment. (Source 21)

How do you get more of it?

This question does not apply in the usual sense: ropinirole is not obtained from food or supplements, and the dose is set by a prescriber. For reference only, the label's restless legs schedule starts at 0.25 mg once daily and titrates to a stated maximum of 4 mg daily, above which safety and effectiveness are not established. (Source 24)

If it is harmful, what reduces it?

Ropinirole is cleared by the liver through the CYP1A2 enzyme and has a half-life of about six hours, so blood levels fall within a day of stopping. Clearance is faster in smokers and slower when a CYP1A2 inhibitor such as ciprofloxacin is taken, which raises exposure. Stopping abruptly, however, can bring on withdrawal symptoms, so the label advises tapering under medical supervision rather than simply halting. (Source 27)

Why might someone be low in it or missing it?

Not applicable as a deficiency: nobody is naturally low in ropinirole. The nearest real-world equivalent is lower blood levels of the drug than expected, which the label attributes to smoking, since tobacco smoke induces CYP1A2. In one restless legs trial smokers had about 30% lower peak concentration and 38% lower total exposure than non-smokers at the same dose. (Source 8)

Which whole foods contain it or feed it?

No whole food contains ropinirole. Food does change how it is absorbed: a high-fat meal does not alter the total amount absorbed but delays the peak by about 2.5 hours and lowers the peak concentration by roughly a quarter. The label also states the tablets can be taken with or without food. (Source 9)

What happens if you do not have it?

Not having ropinirole causes no deficiency; it means the underlying condition is untreated or treated another way. For Parkinson's disease, levodopa gave slightly better patient-rated mobility than agonist-first treatment in the PD MED trial, so not taking a dopamine agonist is not the same as having no option. Stopping it after a period of use is different from never taking it: withdrawal symptoms including insomnia, anxiety, depression, fatigue, sweating and pain have been reported, and they generally do not respond to levodopa. (Source 11)

How can you test for it?

There is no routine blood test used to guide ropinirole therapy, and the label sets no monitoring level. What is monitored is clinical: symptom scales such as the IRLS for restless legs, and structured questioning for impulse control problems and for augmentation. The 66-week augmentation study used the Structured Interview for the Diagnosis of Augmentation, the Augmentation Severity Rating Scale and blinded expert panel review against NIH diagnostic criteria, which gives an idea of how much work a reliable assessment takes. (Source 15)

References

1. DailyMed / US FDA Structured Product Label. Ropinirole tablet, film coated - FDA prescribing information (Alembic Pharmaceuticals Inc., SPL version 22, published Sep 30, 2026) - section 12.1 Mechanism of Action. 2026. Read the source
2. The New England journal of medicine. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. [Results section of the abstract]. 2000. PMID 10816186, DOI 10.1056/nejm200005183422004. Read the source
3. The Cochrane database of systematic reviews. Ropinirole for levodopa-induced complications in Parkinson's disease. [Main results section of the abstract]. 2000. PMID 10908503, DOI 10.1002/14651858.cd001516. Read the source
4. The Cochrane database of systematic reviews. Dopamine agonists for restless legs syndrome. [Main results section of the abstract]. 2011. PMID 21412893, DOI 10.1002/14651858.cd006009.pub2. Read the source
5. Cell stem cell. Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery. [Abstract section of the abstract]. 2023. PMID 37267913, DOI 10.1016/j.stem.2023.04.017. Read the source
6. DailyMed / US FDA Structured Product Label. Ropinirole tablet, film coated - FDA prescribing information (Alembic Pharmaceuticals Inc., SPL version 22, published Sep 30, 2026) - section 12.3 Pharmacokinetics, drug interaction studies subsection. 2026. Read the source
7. DailyMed / US FDA Structured Product Label. Ropinirole tablet, film coated - FDA prescribing information (Alembic Pharmaceuticals Inc., SPL version 22, published Sep 30, 2026) - section 7.2 Estrogens. 2026. Read the source
8. DailyMed / US FDA Structured Product Label. Ropinirole tablet, film coated - FDA prescribing information (Alembic Pharmaceuticals Inc., SPL version 22, published Sep 30, 2026) - section 12.3 Pharmacokinetics, Cigarette Smoking subsection. 2026. Read the source
9. DailyMed / US FDA Structured Product Label. Ropinirole tablet, film coated - FDA prescribing information (Alembic Pharmaceuticals Inc., SPL version 22, published Sep 30, 2026) - section 12.3 Pharmacokinetics, Absorption subsection. 2026. Read the source
10. DailyMed / US FDA Structured Product Label. Ropinirole tablet, film coated - FDA prescribing information (Alembic Pharmaceuticals Inc., SPL version 22, published Sep 30, 2026) - section 17 Patient Counseling Information, Falling Asleep during Activities of Daily Living and Somnolence. 2026. Read the source
11. DailyMed / US FDA Structured Product Label. Ropinirole tablet, film coated - FDA prescribing information (Alembic Pharmaceuticals Inc., SPL version 22, published Sep 30, 2026) - section 5.8 Withdrawal Symptoms. 2026. Read the source
12. Clinical parkinsonism & related disorders. Dopamine agonist withdrawal syndrome associated factors: A retrospective chart review. [Abstract section of the abstract]. 2022. PMID 35909701, DOI 10.1016/j.prdoa.2022.100153. Read the source
13. DailyMed / US FDA Structured Product Label. Ropinirole tablet, film coated - FDA prescribing information (Alembic Pharmaceuticals Inc., SPL version 22, published Sep 30, 2026) - section 5.9 Augmentation and Early-Morning Rebound in Restless Legs Syndrome. 2026. Read the source
14. The Cochrane database of systematic reviews. Dopamine agonist therapy in early Parkinson's disease. [Main results section of the abstract]. 2008. PMID 18425954, DOI 10.1002/14651858.cd006564.pub2. Read the source
15. Movement disorders : official journal of the Movement Disorder Society. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. [Abstract section of the abstract]. 2012. PMID 22328464, DOI 10.1002/mds.24889. Read the source
16. Archives of neurology. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. [Results section of the abstract]. 2010. PMID 20457959, DOI 10.1001/archneurol.2010.65. Read the source
17. Archives of neurology. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. [Conclusions section of the abstract]. 2010. PMID 20457959, DOI 10.1001/archneurol.2010.65. Read the source
18. DailyMed / US FDA Structured Product Label. Ropinirole tablet, film coated - FDA prescribing information (Alembic Pharmaceuticals Inc., SPL version 22, published Sep 30, 2026) - section 5.6 Impulse Control/Compulsive Behaviors. 2026. Read the source
19. DailyMed / US FDA Structured Product Label. Ropinirole tablet, film coated - FDA prescribing information (Alembic Pharmaceuticals Inc., SPL version 22, published Sep 30, 2026) - section 6.1 Clinical Trials Experience, early Parkinson's disease narrative. 2026. Read the source
20. DailyMed / US FDA Structured Product Label. Ropinirole tablet, film coated - FDA prescribing information (Alembic Pharmaceuticals Inc., SPL version 22, published Sep 30, 2026) - section 6.1 Clinical Trials Experience, advanced Parkinson's disease narrative. 2026. Read the source
21. Lancet (London, England). Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. [Findings section of the abstract]. 2014. PMID 24928805, DOI 10.1016/s0140-6736(14)60683-8. Read the source
22. Lancet (London, England). Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. [Interpretation section of the abstract]. 2014. PMID 24928805, DOI 10.1016/s0140-6736(14)60683-8. Read the source
23. The Cochrane database of systematic reviews. Dopamine agonist therapy in early Parkinson's disease. [Authors' conclusions section of the abstract]. 2008. PMID 18425954, DOI 10.1002/14651858.cd006564.pub2. Read the source
24. DailyMed / US FDA Structured Product Label. Ropinirole tablet, film coated - FDA prescribing information (Alembic Pharmaceuticals Inc., SPL version 22, published Sep 30, 2026) - section 2.3 Dosing for Restless Legs Syndrome, opening paragraph. 2026. Read the source
25. DailyMed / US FDA Structured Product Label. Ropinirole tablet, film coated - FDA prescribing information (Alembic Pharmaceuticals Inc., SPL version 22, published Sep 30, 2026) - section 2.2 Dosing for Parkinson's Disease, opening paragraph. 2026. Read the source
26. DailyMed / US FDA Structured Product Label. Ropinirole tablet, film coated - FDA prescribing information (Alembic Pharmaceuticals Inc., SPL version 22, published Sep 30, 2026) - Highlights, Indications and Usage excerpt. 2026. Read the source
27. DailyMed / US FDA Structured Product Label. Ropinirole tablet, film coated - FDA prescribing information (Alembic Pharmaceuticals Inc., SPL version 22, published Sep 30, 2026) - section 7.1 Cytochrome P450 1A2 Inhibitors and Inducers. 2026. Read the source